Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $93.33.

PBH has been the subject of a number of research analyst reports. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Royal Bank of Canada increased their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a research note on Friday, March 21st. DA Davidson lifted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, February 7th. StockNews.com downgraded Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 8th. Finally, Oppenheimer increased their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock opened at $82.17 on Friday. The stock has a 50 day moving average of $84.56 and a 200 day moving average of $79.83. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $90.04. The firm has a market cap of $4.07 billion, a PE ratio of 19.24, a PEG ratio of 2.69 and a beta of 0.47. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors have recently made changes to their positions in PBH. Allspring Global Investments Holdings LLC lifted its stake in shares of Prestige Consumer Healthcare by 3.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after buying an additional 49,331 shares in the last quarter. Geode Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after buying an additional 21,951 shares during the period. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at approximately $84,932,000. Invesco Ltd. raised its holdings in shares of Prestige Consumer Healthcare by 2.4% in the 4th quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock valued at $82,796,000 after buying an additional 24,392 shares during the period. Finally, Congress Asset Management Co. increased its stake in Prestige Consumer Healthcare by 9.1% during the first quarter. Congress Asset Management Co. now owns 991,580 shares of the company’s stock worth $85,246,000 after purchasing an additional 82,838 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.